Publications by authors named "Michele-Vera Yonga"

Substance use disorders (SUDs) and anxiety disorders (ADs) are highly comorbid, a co-occurrence linked to worse clinical outcomes than either condition alone. While the neurobiological mechanisms involved in SUDs and anxiety disorders are intensively studied separately, the mechanisms underlying their comorbidity remain an emerging area of interest. This narrative review explores the neurobiological processes underlying this comorbidity, using the Research Domain Criteria (RDoC) framework to map disruptions in positive valence, negative valence, and cognitive systems across the three stages of the addiction cycle: binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation.

View Article and Find Full Text PDF

The rewarding effects of stimulant drugs such as methylphenidate (MP) depend crucially on how fast they raise dopamine in the brain. Yet how the rate of drug-induced dopamine increases impacts brain network communication remains unresolved. We manipulated route of MP administration to generate fast versus slow dopamine increases.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how the amplitude of low-frequency fluctuations (ALFF) and global functional connectivity density (gFCD) are affected by variations in dopamine levels after administering methylphenidate (MP).
  • The research used simultaneous PET-fMRI scanning on participants receiving either a placebo, intravenous (IV), or oral methylphenidate, revealing that IV-MP significantly altered brain activity metrics compared to oral administration.
  • Results showed that gFCD relates to both the increase in dopamine levels and the rate at which it rises, while ALFF is only sensitive to the overall level of dopamine, indicating that these measures reflect different aspects of brain activation in response to stimulants.
View Article and Find Full Text PDF

The faster a drug enters the brain, the greater its addictive potential, yet the brain circuits underlying the rate dependency to drug reward remain unresolved. With simultaneous PET-fMRI we linked dynamics of dopamine signaling, brain activity/connectivity, and self-reported 'high' in 20 adults receiving methylphenidate orally (results in slow delivery) and intravenously (results in fast delivery) (trial NCT03326245). We estimated speed of striatal dopamine increases to oral and IV methylphenidate and then tested where brain activity was associated with slow and fast dopamine dynamics (primary endpoint).

View Article and Find Full Text PDF
Article Synopsis
  • Dopamine plays a key role in cognition and the brain's reward system, with methylphenidate being a common treatment for ADHD that can also have addictive properties.
  • This study explores how the speed of dopamine release in the brain differs when methylphenidate is taken intravenously versus orally, using simulations and PET scan data.
  • Findings indicate that intravenous methylphenidate leads to quicker and more intense dopamine spikes in the striatum compared to oral intake, correlating with stronger feelings of euphoria ("high").
View Article and Find Full Text PDF

Here we assessed changes in subcortical volumes in alcohol use disorder (AUD). A simple morphometry-based classifier (MC) was developed to identify subcortical volumes that distinguished 32 healthy controls (HCs) from 33 AUD patients, who were scanned twice, during early and later withdrawal, to assess the effect of abstinence on MC-features (Discovery cohort). We validated the novel classifier in an independent Validation cohort (19 AUD patients and 20 HCs).

View Article and Find Full Text PDF